Your browser doesn't support javascript.
loading
Performance-enhancing drugs: understanding the risks.
Hatton, Caroline K; Green, Gary A; Ambrose, Peter J.
Affiliation
  • Hatton CK; Sports Antidoping Science Consultant, PO Box 4795, Culver City, CA 90231, USA. Electronic address: ckhatton@aol.com.
  • Green GA; Division of Sports Medicine, Pacific Palisades Medical Group, University of California, Los Angeles, 15200 Sunset Boulevard, Suite 107, Pacific Palisades, CA 90272, USA.
  • Ambrose PJ; Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, 450 Parnassus Avenue, San Francisco, CA 94143, USA.
Phys Med Rehabil Clin N Am ; 25(4): 897-913, 2014 Nov.
Article in En | MEDLINE | ID: mdl-25442165
ABSTRACT
To help clinicians understand the risks associated with performance-enhancing drugs, this overview covers prohibited lists of substances and methods, therapeutic use exemptions, the legitimate indications and adverse effects, including for megadose and polypharmacy doping of stimulants, anabolic steroids, erythropoiesis-stimulating agents, and growth hormone and ways in which physicians or patients risk committing anti-doping rule violations inadvertently.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Risk Assessment / Dietary Supplements / Doping in Sports / Performance-Enhancing Substances Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Year: 2014 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Risk Assessment / Dietary Supplements / Doping in Sports / Performance-Enhancing Substances Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Year: 2014 Type: Article